Johnson & Johnson unit collaborates with Chinese pharma company to sell cancer therapy drug

Janssen Biotech, a unit of New Brunswick-based Johnson & Johnson, has partnered with China-based Legend Biotech USA and Legend Biotech Ireland to collaborate on a new cancer drug, LCAR-B38M, which is meant to be used in conjunction with CAR-T cell cancer therapy. CAR-T cell therapy is a new, immunological treatment for sufferers of a rare form of cancer called multiple myeloma, which was usually a death sentence. In November, John Theurer Cancer Center became the first New Jersey-based medical facility in the state to offer the life-saving treatment after engaging in a research partnership with New York’s Memorial Sloan Kettering Cancer Center.

Read full article on